Phase II study of rhizoxin in squamous cell head and neck cancer

British Journal of Cancer

Volumn 73, Issue 3, 1996, Pages 400-402

  Verweij, J ^a   Wanders, J ^b   Gil, Th ^c   Schoffski P ^d   Catimel, G ^e   Te Velde, A ^b   De Mulder, P H M ^f  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b EORTC New Drug Development Office   (Netherlands)

^c JULES BORDET INSTITUTE   (Belgium)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e CENTRE LÉON BÉRARD   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Phase II; Rhizoxin

Indexed keywords

ANTINEOPLASTIC AGENT; RHIZOXIN;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PAIN; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA;

EID: 0030067375     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.69     Document Type: Article

References (8)

1. BISSETT D, GRAHAM MA, SETANOIANS A, CHADWICK GA, WILSON P, KOIER IJ, HENRAR R, SCHWARTSMANN G, CASSIDY J, KAYE SB AND KERR DJ. (1992). Phase I and pharmacokinetic study of rhizoxin. Cancer Res. 52, 2894-2898.
2. CLAVEL M AND MAGED MANSOUR AR. (1991). Head and neck cancer: prognostic factors for response to chemotherapy. Eur. J. Cancer, 27, (3), 349-356.
3. HENDRIKS HR, PLOWMAN J, BERGER DP, PAULL KD, FIEBIG HH, FODSTAD O, DREEF-VAN DER MEULEN HC, HENRAR REC, PINEDO HM AND SCHWARTSMANN G. (1992). Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann. Oncol., 3, 755-763.
4. IWASAKI S, KOBAYASHI H, FURUKAWA J, NAMIKOSHI M, OKUDA S, SATO Z, MATSUDA I AND NODA T. (1984). Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin 'rhizoxin' produced by Rhizopus chinensis. J. Antibiot. Tokyo., 37, 354-362.
5. KIYOTO S, KAWAI Y, KAWAKITA T, KINO E, OKUHARA M, UCHIDA I, TANAKA H, HASHIMOTO M, TERANO H, KOHSAKA M, AOKI H AND IMANAKA H. (1986). A new anti-tumour complex, WF-1360, WF-1360 A, B, C, D, E and F. J. Antbiot., 39, 762-772.
6. MATSUDA I, SATO Z, IWASAKI S, OKUDA S, TSURUO T, SASAGAWA K, SHIMIZU F, OHNISHI K AND ARAKAWA M. (1984). Anti-tumour activity of rhizoxin. 43rd Ann. Meeting Japanese Cancer Soc., p. 283.
7. TAKAHASHI M, IWASAKI S, KOBAYASHI H, OKUDA S, MURAI T AND SATO Y. (1987). Rhizoxin binding to tubulin at the maytansine-binding site. Biachem. Biophys. Acat, 926, 215-223.
8. TSURUO T, OH-HARA T, IIDA H, TSUKAGOSHI S, SATO Z, MATSUDA I, IWASAKI S, OKUDA S, SHIMIZU K, SASAGAWA K, FUKAMI M, FUKUDA K AND ARAKAWA M. (1986). Rhizoxin, a macrocyclic lactone antibiotic, as a new anti-tumour agent against human and murine tumour cells and their vincristine-resistant sublines. Cancer Res., 46, 381-385.